Mouse Genetics & Genomics: Development & Disease
October 29 – November 2, 2008
Cold Spring Harbor Laboratory (CSHL)
One Bungtown Road
Cold Spring Harbor, NY 11724
You are cordially invited to participate in the twenty-first annual meeting on Mouse Genetics & Genomics: Development & Disease, which will be held at Cold Spring Harbor Laboratory. The meeting will begin with dinner and the first session on the evening of Wednesday, October 29, 2008, and will conclude with lunch on Sunday, November 2. The specific goal of this conference is to bring together a diverse group of scientists studying various molecular and genetic aspects of mammalian development. This meeting is intended to provide a format for the exchange of ideas and information, to discuss the latest research findings and technical advances towards the study of mammalian development and disease.
Minimize Risk & Maximize Economic Benefits
November 5-6, 2008
Sponsored by Cambridge Healthtech Institute
Pharmacogenomics is being implemented now and is already have an impact in the clinical setting and in healthcare. Employing a pharmacogenomics strategy with marketed drugs can mitigate risk by avoiding adverse events, allowing the identification of patients most likely to benefit from a drug, and thereby improving patient compliance and safety. Tangible benefits of pharmacogenomics and resequencing technologies will be presented, and the value of this approach will be demonstrated. The regulatory perspective will be covered from the US, Europe, and Canada. In the future, a confluence of diagnostic testing, drugs and information will be required to bring new medicines to market. This meeting will show how to apply pharmacogenomics to practice.
Analysis of gene expression in a developmental context emphasizes distinct biological leitmotifs in human cancers
8 July 2008
In recent years, the molecular underpinnings of the long observed resemblance between neoplastic and immature tissue have begun to emerge. Genome-wide transcriptional profiling has revealed similar gene expression signatures in several tumor types and early developmental stages of their tissue of origin. However, it remains unclear whether such a relationship is a universal feature of malignancy, whether heterogeneities exist in the developmental component of different tumor types and to which degree the resemblance between cancer and development is a tissue-specific phenomenon.
Functional Characterization of Genetic Variants and Interactions: The Genes, Environment and Health Initiative (R21)
The National Institute on Drug Abuse on behalf of the NIH Genes, Environment and Health Initiative encourages functional characterization of genetic variants that have been statistically nominated to be associated with a particular outcome through common, complex disease gene discovery approaches, such as genome-wide association studies, candidate gene approaches, or sequencing studies. This FOA supports research relating genetic variation to biological mechanism, or disease causality. Areas of interest include, but are not limited to, relatively low throughput approaches (e.g. transgenic mouse approaches) to test some of the most promising variants for changes in function; or exploit high-throughput tests (e.g. yeast, C. elegans, cell culture systems, or computational approaches) to look at different aspects of variant function.
Release/Posted Date: April 24, 2008
Opening Date: September 17, 2008 (Earliest date an application may be submitted to Grants.gov)
Letters of Intent Receipt Date(s): September 17, 2008
NOTE: On-time submission requires that applications be successfully submitted to Grants.gov no later than 5:00 p.m. local time (of the applicant institution/organization).
Application Due Date(s): October 17, 2008
Peer Review Date(s): January/February 2009
Council Review Date(s): May 2009
Earliest Anticipated Start Date(s): July 2009
Additional Information To Be Available Date (Activation Date): Not Applicable
Expiration Date: October 18, 2008